Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial

<p>Abstract</p> <p>Background</p> <p>Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may lower blood pressure. H...

Full description

Bibliographic Details
Main Authors: Asher Gary N, Viera Anthony J, Weaver Mark A, Dominik Rosalie, Caughey Melissa, Hinderliter Alan L
Format: Article
Language:English
Published: BMC 2012-03-01
Series:BMC Complementary and Alternative Medicine
Subjects:
Online Access:http://www.biomedcentral.com/1472-6882/12/26
id doaj-502bf89d1fc8481fb4e4c1b033513427
record_format Article
spelling doaj-502bf89d1fc8481fb4e4c1b0335134272020-11-25T03:28:59ZengBMCBMC Complementary and Alternative Medicine1472-68822012-03-011212610.1186/1472-6882-12-26Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trialAsher Gary NViera Anthony JWeaver Mark ADominik RosalieCaughey MelissaHinderliter Alan L<p>Abstract</p> <p>Background</p> <p>Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may lower blood pressure. However, there is little published evidence to guide its dosing. The blood pressure lowering effect of hawthorn has been linked to nitric oxide-mediated vasodilation. The aim of this study was to investigate the relationship between hawthorn extract dose and brachial artery flow mediated dilation (FMD), an indirect measure of nitric oxide release.</p> <p>Methods</p> <p>We used a four-period cross-over design to evaluate brachial artery FMD in response to placebo or hawthorn extract (standardized to 50 mg oligomeric procyanidin per 250 mg extract). Randomly sequenced doses of hawthorn extract (1000 mg, 1500 mg, and 2500 mg) and placebo were assigned to each participant. Doses were taken twice daily for 3 1/2 days followed by FMD and a 4-day washout before proceeding to the next dosing period.</p> <p>Results</p> <p>Twenty-one prehypertensive or mildly hypertensive adults completed the study. There was no evidence of a dose-response effect for our main outcome (FMD percent) or any of our secondary outcomes (absolute change in brachial artery diameter and blood pressure). Most participants indicated that if given evidence that hawthorn could lower their blood pressure, they would be likely to use it either in conjunction with or instead of lifestyle modification or anti-hypertensive medications.</p> <p>Conclusion</p> <p>We found no evidence of a dose-response effect of hawthorn extract on FMD. If hawthorn has a blood pressure lowering effect, it is likely to be mediated via an NO-independent mechanism.</p> <p>Trial Registration</p> <p>This trial has been registered with ClinicalTrials.gov, a service of the U.S. National Institutes of Health: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01331486">NCT01331486</a>.</p> http://www.biomedcentral.com/1472-6882/12/26HawthornCrataegushypertensionprehypertensionflow mediated dilationPhase I
collection DOAJ
language English
format Article
sources DOAJ
author Asher Gary N
Viera Anthony J
Weaver Mark A
Dominik Rosalie
Caughey Melissa
Hinderliter Alan L
spellingShingle Asher Gary N
Viera Anthony J
Weaver Mark A
Dominik Rosalie
Caughey Melissa
Hinderliter Alan L
Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
BMC Complementary and Alternative Medicine
Hawthorn
Crataegus
hypertension
prehypertension
flow mediated dilation
Phase I
author_facet Asher Gary N
Viera Anthony J
Weaver Mark A
Dominik Rosalie
Caughey Melissa
Hinderliter Alan L
author_sort Asher Gary N
title Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
title_short Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
title_full Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
title_fullStr Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
title_full_unstemmed Effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
title_sort effect of hawthorn standardized extract on flow mediated dilation in prehypertensive and mildly hypertensive adults: a randomized, controlled cross-over trial
publisher BMC
series BMC Complementary and Alternative Medicine
issn 1472-6882
publishDate 2012-03-01
description <p>Abstract</p> <p>Background</p> <p>Hawthorn extract has been used for cardiovascular diseases for centuries. Recent trials have demonstrated its efficacy for the treatment of heart failure, and the results of several small trials suggest it may lower blood pressure. However, there is little published evidence to guide its dosing. The blood pressure lowering effect of hawthorn has been linked to nitric oxide-mediated vasodilation. The aim of this study was to investigate the relationship between hawthorn extract dose and brachial artery flow mediated dilation (FMD), an indirect measure of nitric oxide release.</p> <p>Methods</p> <p>We used a four-period cross-over design to evaluate brachial artery FMD in response to placebo or hawthorn extract (standardized to 50 mg oligomeric procyanidin per 250 mg extract). Randomly sequenced doses of hawthorn extract (1000 mg, 1500 mg, and 2500 mg) and placebo were assigned to each participant. Doses were taken twice daily for 3 1/2 days followed by FMD and a 4-day washout before proceeding to the next dosing period.</p> <p>Results</p> <p>Twenty-one prehypertensive or mildly hypertensive adults completed the study. There was no evidence of a dose-response effect for our main outcome (FMD percent) or any of our secondary outcomes (absolute change in brachial artery diameter and blood pressure). Most participants indicated that if given evidence that hawthorn could lower their blood pressure, they would be likely to use it either in conjunction with or instead of lifestyle modification or anti-hypertensive medications.</p> <p>Conclusion</p> <p>We found no evidence of a dose-response effect of hawthorn extract on FMD. If hawthorn has a blood pressure lowering effect, it is likely to be mediated via an NO-independent mechanism.</p> <p>Trial Registration</p> <p>This trial has been registered with ClinicalTrials.gov, a service of the U.S. National Institutes of Health: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01331486">NCT01331486</a>.</p>
topic Hawthorn
Crataegus
hypertension
prehypertension
flow mediated dilation
Phase I
url http://www.biomedcentral.com/1472-6882/12/26
work_keys_str_mv AT ashergaryn effectofhawthornstandardizedextractonflowmediateddilationinprehypertensiveandmildlyhypertensiveadultsarandomizedcontrolledcrossovertrial
AT vieraanthonyj effectofhawthornstandardizedextractonflowmediateddilationinprehypertensiveandmildlyhypertensiveadultsarandomizedcontrolledcrossovertrial
AT weavermarka effectofhawthornstandardizedextractonflowmediateddilationinprehypertensiveandmildlyhypertensiveadultsarandomizedcontrolledcrossovertrial
AT dominikrosalie effectofhawthornstandardizedextractonflowmediateddilationinprehypertensiveandmildlyhypertensiveadultsarandomizedcontrolledcrossovertrial
AT caugheymelissa effectofhawthornstandardizedextractonflowmediateddilationinprehypertensiveandmildlyhypertensiveadultsarandomizedcontrolledcrossovertrial
AT hinderliteralanl effectofhawthornstandardizedextractonflowmediateddilationinprehypertensiveandmildlyhypertensiveadultsarandomizedcontrolledcrossovertrial
_version_ 1724581535381716992